Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2025 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

Aptose has received an additional advance of US$2.0M from Hanmi Pharmaceutical Co. as part of a US$8.5M loan facility agreement.
July 01, 2025 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Upgraded to Trade on OTCQB Market

Aptose Upgraded to Trade on OTCQB Market
June 20, 2025 07:52 ET | Source: Aptose Biosciences, Inc.

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

Aptose and Hanmi Pharmaceutical Enter New Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
June 12, 2025 12:00 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2
May 27, 2025 17:53 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Results from Annual and Special Meeting of Shareholders
May 20, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

Aptose Announces Positive CSRC Approval to Dose Escalate to 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline AML
May 14, 2025 13:07 ET | Source: Aptose Biosciences, Inc.

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Selected for Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at EHA2025
May 05, 2025 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial